CIK Cell Therapy for Relapsed or Refractory Acute B-Lymphoblastic Leukemia: Prognostic Impact on Patients With Early CAR-T Cell Dysfunction

Conditions: B-cell Acute Lymphoblastic Leukemia; Acute Lymphoblastic Leukemia, in Relapse; Refractory Acute Lymphoid Leukemia Interventions: Drug: peripheral blood lymphocytes; Drug: CIK cell Sponsors: Beijing GoBroad Hospital Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials